Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00396474
Status:
WITHDRAWN
Last Update Posted:
2015-04-22
First Post:
2006-11-06
Brief Title:
Safety Study In Patients Who Were Born Small And Short And Were Treated With Growth Hormone To Achieve Normal Height
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Long-Term Metabolic Risk In Small for Gestational Age SGA Patients After Growth Hormone Treatment Compared To Matched Untreated Controls
Status:
WITHDRAWN
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study design no longer relevant and no patients were recruited
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to demonstrate that insulin sensitivity is not different between growth hormone - treated subjects who are small for gestational age SGA and an SGA cohort of subjects matched by gender and body mass index BMI who are not treated with growth hormone GH and who remain short at final height
Detailed Description:
case-control
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None